Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Fragment Based Lead Discovery

John Christopher's Biography

John Christopher, Associate Director, Heptares Therapeutics Limited

After a Synthetic Organic Chemistry PhD (with Prof. Philip J. Kocienski, Glasgow, UK) John started his medicinal chemistry career at GlaxoWellcome / GSK, Stevenage, UK in 2000, in the kinase hit-discovery and hit-to-lead area. After five years as lead chemist and program leader for several kinase targets and establishing a kinase fragment screening set, John moved to lead a flexible hit-to-lead group working across multiple target classes (kinases, ion channels, enzyme targets and GPCRs). In 2007 he joined the Immuno-Inflammation area where after initially focusing on GPCR targets he led a protein-protein interaction lead optimisation programme. After leaving GSK in 2009, John joined Heptares Therapeutics (Welwyn Garden City, UK) where he is currently working in lead optimisation on a CNS GPCR target and is responsible for Heptares’ fragment screening collection.

John Christopher Image

Fragment Based Approaches to GPCRs

Tuesday, 13 March 2012 at 16:30

Add to Calendar ▼2012-03-13 16:30:002012-03-13 17:30:00Europe/LondonFragment Based Approaches to

An overview of Heptares’ proprietary GPCR stabilisation technology will be presented, together with examples of how the approach has opened up the GPCR target class to hit discovery through fragment screening.

Add to Calendar ▼2012-03-13 00:00:002012-03-14 00:00:00Europe/LondonFragment Based Lead